CL2017002911A1 - Tratamiento de la hipoglucemia posbariátrica con antagonistas de glp-1. - Google Patents

Tratamiento de la hipoglucemia posbariátrica con antagonistas de glp-1.

Info

Publication number
CL2017002911A1
CL2017002911A1 CL2017002911A CL2017002911A CL2017002911A1 CL 2017002911 A1 CL2017002911 A1 CL 2017002911A1 CL 2017002911 A CL2017002911 A CL 2017002911A CL 2017002911 A CL2017002911 A CL 2017002911A CL 2017002911 A1 CL2017002911 A1 CL 2017002911A1
Authority
CL
Chile
Prior art keywords
treatment
hypoglucemia
glp1ra
hyperinsulinemic
prevention
Prior art date
Application number
CL2017002911A
Other languages
English (en)
Inventor
Tracey L Mclaughlin
Colleen M Craig
Original Assignee
The Bot Of The Leland Stanford Junior Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Bot Of The Leland Stanford Junior Univ filed Critical The Bot Of The Leland Stanford Junior Univ
Publication of CL2017002911A1 publication Critical patent/CL2017002911A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>EL TRATAMIENTO DE LA HIPOGLUCEMIA HIPERINSULINÉMICA COMPRENDE LA ADMINISTRACIÓN DE UNA CANTIDAD EFICAZ DE UN ANTAGONISTA DEL RECEPTOR DEL PÉPTIDO SIMILAR AL GLUCAGÓN 1 (GLP1RA) SOLO O EN COMBINACIÓN CON UN AGENTE AMILINOMIMÉTICO O CUALQUIER AGENTE DE VACIADO ANTIGÁSTRICO. LOS PACIENTES QUE PADECEN HIPOGLUCEMIA HIPERINSULINÉMICA DESPUÉS DE LA CIRUGÍA BARIÁTRICA EXPERIMENTAN UN BENEFICIO PARTICULAR, YA QUE NO EXISTE UN MÉTODO ACTUAL EFICAZ PARA SU TRATAMIENTO. LA PREVENCIÓN O REDUCCIÓN DE LOS EFECTOS ADVERSOS AGUDOS DE LA HIPOGLUCEMIA POSPRANDIAL, TALES COMO PALPITACIONES, TEMBLORES, DEBILIDAD, SUDORACIÓN, CONFUSIÓN, FATIGA, VISIÓN BORROSA, CONVULSIONES O PÉRDIDA DEL CONOCIMIENTO, Y LA PREVENCIÓN DE LOS EFECTOS ADVERSOS CRÓNICOS DE LA HIPOGLUCEMIA HIPERINSULINÉMICA, TALES COMO DETERIORO COGNITIVO, PUEDE LOGRARSE MEDIANTE EL TRATAMIENTO CON GLP1RA.</p>
CL2017002911A 2015-05-22 2017-11-16 Tratamiento de la hipoglucemia posbariátrica con antagonistas de glp-1. CL2017002911A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562165743P 2015-05-22 2015-05-22
US201562254175P 2015-11-11 2015-11-11
US201662329850P 2016-04-29 2016-04-29

Publications (1)

Publication Number Publication Date
CL2017002911A1 true CL2017002911A1 (es) 2018-05-25

Family

ID=57393681

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017002911A CL2017002911A1 (es) 2015-05-22 2017-11-16 Tratamiento de la hipoglucemia posbariátrica con antagonistas de glp-1.
CL2017002913A CL2017002913A1 (es) 2015-05-22 2017-11-16 Tratamiento de la hipoglucemia posbariátrica con exendina (9-39)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2017002913A CL2017002913A1 (es) 2015-05-22 2017-11-16 Tratamiento de la hipoglucemia posbariátrica con exendina (9-39)

Country Status (18)

Country Link
US (10) US10660937B2 (es)
EP (4) EP3978011B1 (es)
AU (6) AU2016267057B2 (es)
BR (2) BR112017025000A2 (es)
CA (2) CA3024358A1 (es)
CL (2) CL2017002911A1 (es)
CY (2) CY1124616T1 (es)
DK (2) DK3297654T3 (es)
ES (2) ES2887723T3 (es)
HR (2) HRP20211768T1 (es)
HU (2) HUE057301T2 (es)
LT (2) LT3297653T (es)
PL (2) PL3297654T3 (es)
PT (2) PT3297653T (es)
RS (2) RS62368B1 (es)
SI (2) SI3297654T1 (es)
SM (2) SMT202100488T1 (es)
WO (2) WO2016191394A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12102663B2 (en) 2015-05-22 2024-10-01 The Board Of Trustees Of The Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with exendin (9-39)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3456340T1 (sl) 2007-01-08 2022-08-31 The Trustees Of The University Of Pennsylvania Antagonisti receptorja za GLP-1 za uporabo pri zdravljenju prirojenega hiperinsulinizma
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
LT3541366T (lt) * 2016-11-21 2025-03-10 Amylyx Pharmaceuticals, Inc. Eksendino (9-39) buferiniai preparatai
US20210030847A1 (en) * 2018-01-23 2021-02-04 Xeris Pharmaceuticals, Inc. Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon
GB201816639D0 (en) * 2018-10-12 2018-11-28 Heptares Therapeutics Ltd GLP-1 Receptor Antagonist
CN112867730A (zh) * 2018-10-15 2021-05-28 艾格尔峰生物制药有限公司 用于治疗高胰岛素低血糖症的阿维西特
EP3908274A1 (en) * 2019-01-11 2021-11-17 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
WO2024042518A1 (en) * 2022-08-21 2024-02-29 M. Arkin (1999) Ltd Glp-1 receptor antagonist and methods of use thereof
CN121219002A (zh) * 2023-04-21 2025-12-26 小利兰斯坦福大学董事会 Glp-1r拮抗作用改善胃肠外科手术后的营养
WO2025235995A1 (en) * 2024-05-10 2025-11-13 The Board Of Trustees Of The Leland Stanford Junior University Use of glp-1 receptor agonists alone or in combination with other gastrointestinal hormones that delay gastric emptying for treatment of postbariatric hypoglycemia

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0969016A2 (en) 1992-06-15 2000-01-05 Scios Inc. Glucagon-like peptide and insulinotropin derivates
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US20040092443A1 (en) 1996-08-06 2004-05-13 Yeda Research And Development Co., Ltd Long-acting exendins and exendin agonists
ATE493998T1 (de) 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
DE122007000044I2 (de) 1997-01-07 2011-05-05 Amylin Pharmaceuticals Inc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
ATE197408T1 (de) 1998-01-30 2000-11-11 Novo Nordisk As Eine injektionsspritze
ATE288268T1 (de) 1998-12-10 2005-02-15 Agouron Pharma Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethoden
US6902744B1 (en) 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
ES2278589T3 (es) 1999-01-14 2007-08-16 Amylin Pharmaceuticals, Inc. Excendinas destinadas a la inhibicion de glucagon.
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6903074B1 (en) 1999-06-04 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Neuromedin b and somatostatin receptor agonists
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
SE0004462D0 (sv) 2000-12-04 2000-12-04 Pharmacia Ab Novel method and use
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
WO2002081649A2 (en) 2001-04-06 2002-10-17 The Trustees Of The University Of Pennsylvania ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
CN1162446C (zh) 2001-05-10 2004-08-18 上海华谊生物技术有限公司 促胰岛素分泌肽衍生物
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
EP1432430A4 (en) 2001-08-28 2006-05-10 Lilly Co Eli PREMIXTURES OF GLP-1 AND BASALINSULIN
US7378385B2 (en) 2002-08-08 2008-05-27 University Of Cincinnati Role for GLP-1 to mediate responses to disparate stressors
WO2004080486A1 (ja) 2003-03-13 2004-09-23 Mitsubishi Pharma Corporation 腫瘍形成抑制剤
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US8617613B2 (en) 2004-04-15 2013-12-31 Alkermes Pharma Ireland Limited Polymer-based sustained release device
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
DE102004043153B4 (de) 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
EP1888031B1 (en) 2005-06-06 2013-01-23 Camurus Ab Glp-1 analogue formulations
PL1971362T3 (pl) 2005-08-19 2015-05-29 Amylin Pharmaceuticals Llc Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
AR060487A1 (es) 2006-04-21 2008-06-18 Xoma Technology Ltd Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
WO2007139941A2 (en) 2006-05-26 2007-12-06 Amylin Pharmaceuticals, Inc. Composition and methods for treatment of congestive heart failure
SI3456340T1 (sl) 2007-01-08 2022-08-31 The Trustees Of The University Of Pennsylvania Antagonisti receptorja za GLP-1 za uporabo pri zdravljenju prirojenega hiperinsulinizma
EP2144649B1 (de) 2007-04-05 2011-07-20 Tecpharma Licensing AG Verabreichungsvorrichtung mit funktionalem antriebsglied
DE102007016811A1 (de) 2007-04-05 2008-10-09 Tecpharma Licensing Ag Vorrichtung zur Verabreichung eines fluiden Wirkstoffes aus einer Mehrkammerampulle
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US20110046053A1 (en) 2008-05-05 2011-02-24 Oramed Ltd. Methods and compositions for oral administration of exenatide
WO2009143285A2 (en) 2008-05-21 2009-11-26 Amylin Pharmaceuticals, Inc. Exendins to lower cholestrol and triglycerides
EP2303226B1 (en) 2008-06-25 2016-03-23 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
WO2010003939A1 (en) * 2008-07-08 2010-01-14 Novartis Ag Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia
SI2341905T2 (sl) 2008-09-04 2024-02-29 Amylin Pharmaceuticals, Llc Formulacije s podaljšanim sproščanjem z uporabo brezvodnih nosilcev
SG174355A1 (en) 2009-04-03 2011-10-28 Nestec Sa Improvement in promotion of healthy catch-up growth
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
WO2012012352A2 (en) 2010-07-19 2012-01-26 Amidebio, Llc Modified peptides and proteins
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20140256626A1 (en) 2011-10-18 2014-09-11 Prolynx Llc Peg conjugates of exenatide
WO2013120022A2 (en) 2012-02-08 2013-08-15 Seneb Biosciences, Inc. Treatment of hypoglycemia
EP4527855A3 (en) 2012-03-26 2025-06-11 Sanofi Stable igg4 based binding agent formulations
US20160185837A1 (en) 2013-08-16 2016-06-30 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
LT3297653T (lt) 2015-05-22 2022-01-10 The Board Of Trustees Of The Leland Stanford Junior University Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
LT3541366T (lt) 2016-11-21 2025-03-10 Amylyx Pharmaceuticals, Inc. Eksendino (9-39) buferiniai preparatai
IL318291A (en) 2022-08-05 2025-03-01 Univ Indiana Res & Tech Corp Glucagon-like peptide 1 receptor antibodies

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12102663B2 (en) 2015-05-22 2024-10-01 The Board Of Trustees Of The Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with exendin (9-39)
US12220444B2 (en) 2015-05-22 2025-02-11 The Board Of Trustees Of The Leland Stanford Junior University Treatment of hyperinsulinemic hypoglycemia with GLP-1 antagonist exendin(9-39)

Also Published As

Publication number Publication date
EP3297653A1 (en) 2018-03-28
LT3297653T (lt) 2022-01-10
HUE055728T2 (hu) 2021-12-28
US11622995B2 (en) 2023-04-11
BR112017024997A2 (pt) 2018-07-31
AU2016267057B2 (en) 2021-12-23
AU2022201973B2 (en) 2025-05-15
HRP20211768T1 (hr) 2022-02-18
US20230346890A1 (en) 2023-11-02
US10660937B2 (en) 2020-05-26
US12220444B2 (en) 2025-02-11
AU2022202506B2 (en) 2025-06-05
CL2017002913A1 (es) 2018-06-01
CY1125147T1 (el) 2023-03-24
DK3297654T3 (da) 2021-09-06
WO2016191394A1 (en) 2016-12-01
EP3297654B1 (en) 2021-07-07
EP3297653A4 (en) 2018-12-26
US20210315974A1 (en) 2021-10-14
SI3297653T1 (sl) 2022-01-31
ES2897955T3 (es) 2022-03-03
HRP20211285T1 (hr) 2022-01-07
EP3936143A1 (en) 2022-01-12
ES2887723T3 (es) 2021-12-27
US10993991B2 (en) 2021-05-04
EP3297653B1 (en) 2021-09-15
RS62627B1 (sr) 2021-12-31
US12102663B2 (en) 2024-10-01
US10639354B2 (en) 2020-05-05
US20200276271A1 (en) 2020-09-03
US20240000894A1 (en) 2024-01-04
US10993992B2 (en) 2021-05-04
US20210290731A1 (en) 2021-09-23
BR112017025000A2 (pt) 2018-08-07
AU2025220813A1 (en) 2025-09-11
SMT202100668T1 (it) 2022-01-10
AU2022201973A1 (en) 2022-04-14
US20180147261A1 (en) 2018-05-31
EP3297654A4 (en) 2018-04-11
PL3297654T3 (pl) 2021-12-20
US20200276272A1 (en) 2020-09-03
AU2016267052A1 (en) 2017-12-14
AU2016267052B2 (en) 2022-01-20
US20250255935A1 (en) 2025-08-14
SMT202100488T1 (it) 2021-11-12
PT3297654T (pt) 2021-09-06
AU2025217292A1 (en) 2025-09-04
LT3297654T (lt) 2021-10-25
SI3297654T1 (sl) 2021-11-30
EP3978011B1 (en) 2026-05-06
HUE057301T2 (hu) 2022-05-28
AU2022202506A1 (en) 2022-05-12
PT3297653T (pt) 2021-10-25
CA3024353A1 (en) 2016-12-01
RS62368B1 (sr) 2021-10-29
CY1124616T1 (el) 2022-07-22
DK3297653T3 (da) 2021-10-18
EP3297654A1 (en) 2018-03-28
CA3024358A1 (en) 2016-12-01
EP3978011A1 (en) 2022-04-06
US11617782B2 (en) 2023-04-04
WO2016191395A1 (en) 2016-12-01
AU2016267057A1 (en) 2017-12-14
PL3297653T3 (pl) 2022-01-31
US20250082730A1 (en) 2025-03-13
US20180117122A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
CL2017002911A1 (es) Tratamiento de la hipoglucemia posbariátrica con antagonistas de glp-1.
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
CL2017003006A1 (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
CL2017002825A1 (es) Formulaciones de tpp1 y métodos para tratar la enfermedad de cln2
MX388380B (es) Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
CO2017004489A2 (es) Polipéptidos fgf-21 modificados
MX2015000990A (es) Analogos del glucagon.
CL2017000982A1 (es) Coagonistas de los receptores de glucagón y de glp-1
CL2017001718A1 (es) Derivados de glucagón con estabilidad mejorada
ECSP17022931A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alchólico
AR103130A1 (es) Sonda de vitrectomía con un escáner de fibra óptica
DOP2015000234A (es) COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C5 DEL COMPLEMENTO Y METODOS PARA SU USO.
CL2013003547A1 (es) Peptido derivado de oxintomodulina; polinucleotido que lo codifica; composicion farmaceutica que lo comprende; uso del peptido para tratar la obesidad.
CL2012001583A1 (es) Preparación oftálmica que comprende: a) povidona yodada, b) un agente refrescante y c) uno o más entre alcanfor, borneol, lubricante, emoliente, antiinflamatorio esteroidal y antinflamatorio no esteroidal; y su uso para el tratamiento y/o profilaxis de un trastorno ocular o una infección.
ZA201906100B (en) Combination of a ppar agonist with a fxr agonist
MX2016010328A (es) Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
GT201700194A (es) Formulación de combinación de tesofensina y betabloqueante
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
CO2018012180A2 (es) Métodos de tratamiento para enfermedades colestásicas y fibróticas
MX394213B (es) Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos.
CL2017001843A1 (es) Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2.
CU20210008A7 (es) Aspirasas solubilizadas
ECSP15009391A (es) siARN Y SU USO EN LOS MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE ENFERMEDADES DE LOS OJOS
MX2018002921A (es) Composicion de hormona foliculo-estimulante mamifera con estabilidad incrementada.
IL251555B (en) Preparations containing nanometer particles for the administration of drugs for the treatment of eye diseases